Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gomis

Showing results (231-240 of 321) with videos related to

Pageof 33
Sort By:
Diabetologia|February 18, 2004
Stable and functional regeneration of pancreatic beta-cell population in nSTZ-rats treated with tungstateJ Fernández-Alvarez, A Barberà, B Nadal, et al.
Diabetologia|August 22, 2002
Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the diseaseF Nicoletti, I Conget, M Di Mauro, et al.
Cell Biochemistry and Function|July 1, 1984
Metabolic and secretory effects of methylamine in pancreatic isletsR Gomis, M Deleers, F Malaisse-Lagae, et al.
Biochemical and Biophysical Research Communications|September 24, 1999
Detection of a new variant of the mitochondrial glycerol-3-phosphate dehydrogenase gene in Spanish type 2 DM patientsM Gudayol, J M Vidal-Taboada, E F Usac, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2011
Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responsesF A Hanzu, M Palomo, S G Kalko, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Endocrine|February 2, 2002
Identification and functional analysis of mutations in FAD-binding domain of mitochondrial glycerophosphate dehydrogenase in caucasian patients with type 2 diabetes mellitusM Gudayol, J Vidal, E F Usac, et al.
Diabetologia|April 1, 1993
Human pancreatic islet function at the onset of type 1 (insulin-dependent) diabetes mellitusI Conget, J Fernández-Alvarez, J Ferrer, et al.
Diabetes Research and Clinical Practice|May 1, 1994
Microalbuminuria development in short-term IDDMJ M González-Clemente, E Esmatjes, P Navarro, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 23, 2007
Rosiglitazone RECORD study: glucose control outcomes at 18 monthsP D Home, N P Jones, S J Pocock, et al.
Pageof 33

Showing results (231-240 of 321) with videos related to

Sort By:
Pageof 33
Diabetologia|February 18, 2004
Stable and functional regeneration of pancreatic beta-cell population in nSTZ-rats treated with tungstateJ Fernández-Alvarez, A Barberà, B Nadal, et al.
Diabetologia|August 22, 2002
Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the diseaseF Nicoletti, I Conget, M Di Mauro, et al.
Cell Biochemistry and Function|July 1, 1984
Metabolic and secretory effects of methylamine in pancreatic isletsR Gomis, M Deleers, F Malaisse-Lagae, et al.
Biochemical and Biophysical Research Communications|September 24, 1999
Detection of a new variant of the mitochondrial glycerol-3-phosphate dehydrogenase gene in Spanish type 2 DM patientsM Gudayol, J M Vidal-Taboada, E F Usac, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2011
Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responsesF A Hanzu, M Palomo, S G Kalko, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Endocrine|February 2, 2002
Identification and functional analysis of mutations in FAD-binding domain of mitochondrial glycerophosphate dehydrogenase in caucasian patients with type 2 diabetes mellitusM Gudayol, J Vidal, E F Usac, et al.
Diabetologia|April 1, 1993
Human pancreatic islet function at the onset of type 1 (insulin-dependent) diabetes mellitusI Conget, J Fernández-Alvarez, J Ferrer, et al.
Diabetes Research and Clinical Practice|May 1, 1994
Microalbuminuria development in short-term IDDMJ M González-Clemente, E Esmatjes, P Navarro, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 23, 2007
Rosiglitazone RECORD study: glucose control outcomes at 18 monthsP D Home, N P Jones, S J Pocock, et al.
Pageof 33